The non-specific cross-reacting antigen (NCA) shares antigenic determinants with CEA but also bears a specific determinant not present on CEA because anti-NCA sera absorbed by CEA continue to precipitate NCA (Mach & Pusztaszeri, 1972; von Kleist et al., 1972; Bordes et al., 1975; Rogers, 1983) . In the last decade NCA has also been found in normal polymorphs and macrophages and then in pathological cells in patients with myelocytic leukaemias (Bordes et al., 1975; Burtin et al., 1975 Burtin et al., , 1979 Heumann et al., 1979; Wahren et al., 1979 Wahren et al., , 1980 Burtin et al., 1980; Pattengale et al., 1980) . It is generally agreed that NCA is a differentiation marker of the myelocytic cell series. However, there is controversy concerning the initial stages of NCA production during myelocytic cell maturation (Burtin et al., 1979; Heumann et al., 1979; Burtin et al., 1980; Wahren et al., 1980) . Using immune sera against CEA and NCA previously characterized (Hartozifiska et al., 1983; Kula et al., 1983) we have studied: (i) the distribution and localization of NCA and CEA in cells of different types of leukaemias and normal donors; (ii) the presence of NCA in individual stages of granulocyte differentiation in chronic (CGL) and acute myeloid leukaemias (AML) and (iii) CEA and NCA serum levels in patients with leukaemias and control donors.
Materials and methods

Patients
Seventeen AML cases were studied, which were classified according to the proposal of the FABCooperative Group (Bennet et al., 1976 The specific anti-CEA and anti-NCA sera were prepared by immunizing goats with purified CEA (Zawadzka et al., 1979) or NCA (Krop-Watorek et al., 1983) as described previously (Harkozinska et al., 1983; Kula et al., 1983 Serum NCA levels were assayed by radioimmunoassay (Gadler et al., 1978) .
The double diffusion test was performed in 1% agarose gel with PCA extracts of normal lung, spleen, and CGL cells at concentrations of 10-50 mg ml -1 and with CEA and NCA at a concentration of 0.1 mg ml-1. To block the activity of anti-NCA serum with PCA extracts of normal tissues or CGL-PCA extract, an additional absorption with the definitive antigen was carried out on an agarose plate (Ibrahim et al., 1979) .
Results
The results of NCA determinations in different types of AML are summarized in Table I (Tables II & III) . The Ficoll-Hypaque density-gradient procedure permitted the separation of myeloid cells according to the degree of morphological maturation so that young forms of granulocytes focused in low-density fractions, whereas polymorphonuclear neutrophils were confined to high-density fractions. This method yielded sufficient immature cells for NCA content analysis and facilitated comparison of the presence of this antigen in different maturation forms of granulocytes both in CGL and in CGL-BC patients (Table III) .
In the individual case presented (Table II ) the blood leukocytes concentrated in the low density fractions of Ficoll-Hypaque contained more detectable NCA than the bone marrow cell fractions studied in parallel. Morphologically, the bone marrow cells of this patient showed distinct cellular rejuvenation in comparison to blood cell preparations. Figure Ic) . Many pathological myelocytes and metamyelocytes were NCA-positive (40-70%) but their number and fluorescence intensity varied from one case to another ( Figure Id) . About 80-90% of mature neutrophils concentrated mainly in fractions 1.09-1.105gml-1 were NCA positive (Figure le) analogous to the finding for the neutrophils of healthy persons (Table III, Figure If) . Interestingly, the percentage of NCA positive cells increased in the more dense Ficoll-Hypaque fractions even within the same morphological forms of granulocytes. By contrast, ALL peripheral blood lymphoblasts were always negative (Table I) .
Anti-CEA serum did not stain cells in any fractions of CGL-BC and CGL cells ( Figure Ig) . Similarly the lymphoid and monocytic cell series were CEA negative.
Serum NCA levels in patients with AML and ALL usually were very low or indetectable (Table  I) in comparison to levels of 30ngml-1 in the sera of normal donors (Table III ). In CGL patients the level of circulating NCA was always elevated to a mean value of 140 ng ml-1, and in one case exceeded 400 ng ml-1. The serum NCA values in patients with myeloblastic crisis of CGL usually amounted lOOngml-1 (Table III) . CEA in plasma was within the normal range (0-7ngml-1) in all studied patients. Table II NCA For other abbreviations see legend to Table I .
The reactivity of anti-NCA serum with PCA extract of CGL-cells,NCA, and CEA standards compared by double immunodiffusion showed identity or immunological relationship of the NCA extracted from leukaemic granulocytes and NCA earlier isolated from normal lung tissues (Figure 2) . Additional absorption on an agarose plate of anti-NCA serum with PCA extracts of normal lung or spleen tissues removed the reactivity of this antiserum not only with the extracts but also with CGL cells. Removing the activity with the the NCA standard was dependent on the concentration of normal tissue PCA extracts used in additional absorptions as an NCA source. 
Discussion
These results demonstrate that: (i) AML blasts lacking the ability to mature (MO type) and monoblasts did not contain NCA; (ii) individual AML blasts with features of maturation (Ml, M2 types) and some blasts from myeloblastic crisis of CGL showed a limited expression of cytoplasmic NCA; (iii) the number of NCA containing cells increased as the more mature granulocyte fractions were isolated on Ficoll-Hypaque density-gradients; and (iv) myelocytic NCA is immunologically related if not identical with NCA isolated from lung tissue.
The stage in which NCA appears in the course of granulocyte differentiation is interesting mainly in relation to understanding the biological role of this glycoprotein. Our studies indicated that NCA appears early in the differentiation process of the myeloid cell series and is detectable in some differentiated myeloblasts (M 1, M2 type leukaemias). These observations are concordant with earlier data of Burtin et al. (1979 Burtin et al. ( , 1980 suggesting that NCA can play a role in protection of granulocytic cells against their own enzymes. Other authors (Heumann et al., 1979; Wahren et al., 1979 Wahren et al., , 1980 were not able to detect NCA in myeloblasts and believed that it is a marker of more mature myeloid cells. Application of densitygradient centrifugation to separate granulocytes permitted the study of NCA distribution in (Frenoy et al., t982) . On the other hand, the ability to secrete NCA into the blood circulation from the myeloid cell series may play an important role in the regulation of the NCA serum level.
According to some authors (Bordes et al., 1975; Heumann et al., 1979; Nap et al., 1983) myelocytic NCA is immunologically identi'cal to NCA isolated from normal lungs. Our preliminary results showed an immunological relationship betweeii lung and myelocytic NCA. However, detailed immunoprecipitation studies revealed some antigenic heterogeneity in NCA molecules since the precipitation lines with anti-NCA serum given by standard NCA and individual extracts of normal lung, spleen, or CGL cells, did not always show complete identity (unpublished data). In our opinion this interesting problem demands more detailed study, especially since recently Chavanel et al. (1983) revealed the existence of at least two epitopes on the specific moiety of NCA.
